Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,718

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,991

The IASLC Lung Cancer Staging Project: Proposals for Revision of the M Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification of Lung Cancer

Postmus, P. E., Brambilla, E. M., Chansky, K., Crowley, J. J., Goldstraw, P. G., Patz, E. F., & Yokomise, H. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31811f4703 · Cited by 1,593

Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma

Yamamoto, Y., Yatsuda, J., Shimokawa, M., Fuji, N., Aoki, A., Sakano, S., Yamamoto, M., Suga, A., Tei, Y., Yoshihiro, S., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01784-w · Cited by 42

Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy

Baker, M. L., Yamamoto, Y., Perazella, M. A., Dizman, N., Shirali, A. C., Hafez, N., Weinstein, J. N., Simonov, M., Testani, J. M., Kluger, H. M., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004421 · Cited by 42

Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy

Rzepecki, A. K., Cheng, H., & McLellan, B. N. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.046 · Cited by 42

Prognostic impact of the Controlling Nutritional Status score in patients with non-small cell lung cancer treated with pembrolizumab

Ohba, T., Takamori, S., Toyozawa, R., Nosaki, K., Umeyama, Y., Haratake, N., Miura, N., Yamaguchi, M., Taguchi, K., Seto, T., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.09.29 · Cited by 42

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck ( CheckMate 141)

Yen, C., Kiyota, N., Hanai, N., Takahashi, S., Yokota, T., Iwae, S., Shimizu, Y., Hong, R., Goto, M., Kang, J., et al. (2020) · Head & Neck · doi:10.1002/hed.26331 · Cited by 41

Immune Checkpoint Inhibitors and Neurotoxicity

Zhao, Z., Zhang, C., Zhou, L., Dong, P., & Shi, L. (2020) · Current Neuropharmacology · doi:10.2174/1570159x19666201230151224 · Cited by 39

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment

Chieng, J. H. L., Htet, Z. W., Zhao, J. J., Tai, E. S., Tay, S. H., Huang, Y., Wong, A. S. C., & Yang, S. P. (2022) · Cancers · doi:10.3390/cancers14112687 · Cited by 40

Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer

Cui, P., Huang, D., Wu, Z., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Huang, Z., Chen, S., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920922033 · Cited by 38

Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic

Friedlaender, A., Kim, C., & Addeo, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00862 · Cited by 38

The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer

Asano, Y., Yamamoto, N., Demura, S., Hayashi, K., Takeuchi, A., Kato, S., Miwa, S., Igarashi, K., Higuchi, T., Yonezawa, H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.871675 · Cited by 38

Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy

Schweizer, C., Schubert, P., Rutzner, S., Eckstein, M., Haderlein, M., Lettmaier, S., Semrau, S., Gostian, A., Frey, B., Gaipl, U. S., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.001 · Cited by 37

Incidence of Skin and Respiratory Immune-Related Adverse Events Correlates With Specific Tumor Types in Patients Treated With Checkpoint Inhibitors

Rose, L. M., DeBerg, H. A., Vishnu, P., Frankel, J., Manjunath, A. B., Flores, J. P., & Aboulafia, D. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.570752 · Cited by 37

A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study

Takada, K., Shimokawa, M., Takamori, S., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., Otsubo, K., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09385-8 · Cited by 34

Real-World Efficacy of First-Line Pembrolizumab in Patients With Advanced or Recurrent Non–Small-Cell Lung Cancer and High PD-L1 Tumor Expression

Tambo, Y., Sone, T., Shibata, K., Nishi, K., Shirasaki, H., Yoneda, T., Araya, T., Kase, K., Nishikawa, S., Kimura, H., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.017 · Cited by 35

Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer

Wang, X., Niu, X., An, N., Sun, Y., & Chen, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.611012 · Cited by 36

Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune-related adverse events in advanced malignant tumors treated with PD-1/PD-L1 inhibitors: a retrospective analysis

Ma, Y., Ma, X., Wang, J., Wu, S., Wang, J., & Cao, B. (2022) · World Journal of Surgical Oncology · doi:10.1186/s12957-022-02695-y · Cited by 34

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade

Tanaka, K., Yanagihara, T., Ikematsu, Y., Inoue, H., Ota, K., Kashiwagi, E., Suzuki, K., Hamada, N., Takeuchi, A., Tatsugami, K., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25743 · Cited by 31

Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors

Fiala, O., Šorejs, O., Šustr, J., Kučera, R., Topolčan, O., & Fínek, J. (2020) · Anticancer Research · doi:10.21873/anticanres.14063 · Cited by 34

Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis

Huang, A., Xu, Y., Zang, X., Wu, C., Gao, J., Sun, X., Xie, M., Ma, X., Deng, H., Song, J., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08353-y · Cited by 33

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Matsumoto, H., Hirano, K., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08048-4 · Cited by 33

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy

He, Y., Lu, M., Che, J., Chu, Q., Zhang, P., & Chen, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.716844 · Cited by 34

Side effects of immunotherapy: a constant challenge for oncologists

Scotté, F., Ratta, R., & Beuzeboc, P. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000541 · Cited by 32

Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck

Kacew, A. J., Harris, E. J., Lorch, J. H., Schoenfeld, J. D., Margalit, D. N., Kass, J. I., Tishler, R. B., Haddad, R. I., & Hanna, G. J. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104676 · Cited by 32

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

Chen, X., Nie, J., Dai, L., Hu, W., Zhang, J., Han, J., Ma, X., Tian, G., Han, S., Wu, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.607531 · Cited by 32

PD‐(L)1 inhibitors vs. chemotherapy vs. their combination in front‐line treatment for NSCLC: An indirect comparison

Liang, H., Liu, Z., Cai, X., Pan, Z., Chen, D., Li, C., Chen, Y., He, J., & Liang, W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32366 · Cited by 31

Microbiota and Lung Cancer. Opportunities and Challenges for Improving Immunotherapy Efficacy

Ocáriz, M., Cruellas, M., Ruiz, M. G., Lastra, R. P., Martínez‐Lostao, L., Ramírez-Labrada, A., Paño, J. R., Sesma, A., Torres, I., Yubero, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.568939 · Cited by 32

Exploiting the obesity-associated immune microenvironment for cancer therapeutics

Desharnais, L., Walsh, L. A., & Quail, D. F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107923 · Cited by 31

Assessment of the albumin-bilirubin grade as a prognostic factor in patients with non-small-cell lung cancer receiving anti-PD-1-based therapy

Takada, K., Takamori, S., Shimokawa, M., Toyokawa, G., Shimamatsu, S., Hirai, F., Tagawa, T., Okamoto, T., Hamatake, M., Tsuchiya‐Kawano, Y., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100348 · Cited by 31

Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis

Tozuka, T., Sugano, T., Noro, R., Takano, N., Hisakane, K., Takahashi, S., Tanaka, T., Kashiwada, T., Takeuchi, S., Kunugi, S., et al. (2018) · Oxford Medical Case Reports · doi:10.1093/omcr/omy094 · Cited by 31

Risk factors for immune‐related adverse events from anti‐PD ‐1 or anti‐ PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients

Huang, Y., Soon, Y. Y., Aminkeng, F., Tay, S. H., Ang, Y. L. E., Kee, A. C.-L., Goh, B. C., Wong, A. S. C., & Soo, R. A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33822 · Cited by 30

Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer

Morita, A., Ichihara, E., Inoue, K., Fujiwara, K., Yokoyama, T., Harada, D., Ando, C., Kano, H., Oda, N., Tamura, T., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.34842 · Cited by 29

Successful Treatment of Nivolumab-related Cholangitis with Prednisolone: A Case Report and Review of the Literature

Sawada, K., Shonaka, T., Nishikawa, Y., Hasegawa, K., Hayashi, H., Hasebe, T., Nakajima, S., Ikuta, K., Fujiya, M., Furukawa, H., et al. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2330-18 · Cited by 29

From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy

Sesma, A., Pardo, J., Cruellas, M., Gálvez, E. M., Ruiz, M. G., Isla, D., Martínez‐Lostao, L., Ocáriz, M., Paño, J. R., Quílez, E., et al. (2020) · Cancers · doi:10.3390/cancers12102974 · Cited by 28

“Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer”: is there a substantial difference or not?

Spagnuolo, A., & Gridelli, C. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.83 · Cited by 28

Association of Immune-Related Adverse Events with Pembrolizumab Efficacy in the Treatment of Advanced Urothelial Carcinoma

Kobayashi, K., Suzuki, K., Hiraide, M., Aoyama, T., Yokokawa, T., Shikibu, S., Hashimoto, K., Iikura, Y., Sato, H., Sugiyama, E., et al. (2020) · Oncology · doi:10.1159/000505340 · Cited by 27

Efficacy and immune-related adverse event associations in avelumab-treated patients

Kelly, K. L., Manitz, J., Patel, M. R., D’Angelo, S. P., Apolo, A. B., Rajan, A., Kasturi, V., Speit, I., Bajars, M., Warth, J. D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001427 · Cited by 27

Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients

Matsuki, T., Okamoto, I., Fushimi, C., Takahashi, H., Okada, T., Kondo, T., Sato, H., Ito, T., Tokashiki, K., Tsukahara, K., et al. (2020) · Cancers · doi:10.3390/cancers12113427 · Cited by 27

The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer

Bredin, P., & Naidoo, J. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10039-1 · Cited by 28

Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review

Zdrenka, M., Kowalewski, A., Ahmadi, N., Sadiqi, R. U., Chmura, Ł., Borowczak, J., Maniewski, M., & Szylberg, Ł. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.9265 · Cited by 30

Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab

Bouhlel, L., Doyen, J., Chamorey, E., Poudenx, M., Ilié, M., Gal, J., Guigay, J., Benzaquen, J., Marquette, C., Berthet, J., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.019 · Cited by 26

Association Between the Occurrence and Spectrum of Immune-Related Adverse Events and Efficacy of Pembrolizumab in Asian Patients With Advanced Urothelial Cancer: Multicenter Retrospective Analyses and Systematic Literature Review

Kijima, T., Fukushima, H., Kusuhara, S., Tanaka, H., Yoshida, S., Yokoyama, M., Ishioka, J., Matsuoka, Y., Numao, N., Sakai, Y., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.07.003 · Cited by 26

Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non–Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis

Li, Y.-L., Zhang, Y., Jia, X., Jiang, P., Mao, Z., Liang, T. B., Du, Y., Zhang, J., Zhang, G., Niu, G., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.004 · Cited by 26

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

Russano, M., Cortellini, A., Giusti, R., Russo, A., Zoratto, F., Rastelli, F., Gelibter, A. J., Chiari, R., Nigro, O., Tursi, M. D., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03045-9 · Cited by 26

The Prognostic Significance of the Continuous Administration of Anti-PD-1 Antibody via Continuation or Rechallenge After the Occurrence of Immune-Related Adverse Events

Fujisaki, T., Watanabe, S., Ota, T., Kushiro, K., Sato, Y., Takahashi, M., Ohtsubo, A., Shoji, S., Nozaki, K., Ichikawa, K., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704475 · Cited by 26

Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings

Yoneda, T., Sone, T., Koba, H., Shibata, K., Suzuki, J., Tani, M., Nishitsuji, M., Nishi, K., Kobayashi, T., Shirasaki, H., et al. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.03.008 · Cited by 26

Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab

Sugisaka, J., Toi, Y., Taguri, M., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., Suzuki, K., et al. (2019) · JMA Journal · doi:10.31662/jmaj.2019-0005 · Cited by 25

Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy

Kubo, T., Hirohashi, Y., Tsukahara, T., Kanaseki, T., Murata, K., Morita, R., & Torigoe, T. (2021) · Immunological Medicine · doi:10.1080/25785826.2021.1976942 · Cited by 25

Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer

Koyama, J., Horiike, A., Yoshizawa, T., Dotsu, Y., Ariyasu, R., Saiki, M., Sonoda, T., Uchibori, K., Nishikawa, S., Kitazono, S., et al. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.04.102 · Cited by 23

Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Liang, Y., Xu, H., Liu, F., Li, L., Lin, C., Zhang, Y., Wang, N., & Wang, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1281645 · Cited by 23

Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina

Martin, C. M., Lupinacci, L., Perazzo, F., Bas, C. A., Carranza, O. E., Puparelli, C., Kowalyszyn, R. D., Magrí, I., Varela, M. S., Richardet, E., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.014 · Cited by 23

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

Serna-­Higuita, L. M., Amaral, T. M. S., Forschner, A., Leiter, U., Flatz, L., Seeber, O., Thomas, I., Garbe, C., Eigentler, T., & Martus, P. (2021) · Cancers · doi:10.3390/cancers13236141 · Cited by 23

Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan

Otsuka, M., Sugihara, S., Mori, S., Hamada, K., Sasaki, Y., Yoshikawa, S., & Kiyohara, Y. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15246 · Cited by 23

Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer

Huang, L., Li, L., Zhou, Y., Yang, Z., Wang, M., Gao, Y., Yang, Y., Yang, F., Liu, B., Hong, X., et al. (2020) · Journal of Cancer · doi:10.7150/jca.49213 · Cited by 23

Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program

Bisschop, C., Wind, T. T., Blank, C. U., Koornstra, R. H. T., Kapiteijn, E., van den Eertwegh, A. J. M., de Groot, J. W. B., Jalving, M., & Hospers, G. A. P. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000271 · Cited by 22

Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study

Vitale, M. G., Pipitone, S., Venturelli, M., Baldessari, C., Porta, C., Iannuzzi, F., Basso, U., Scagliarini, S., Zucali, P. A., Galli, L., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.05.010 · Cited by 22

Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors

Kanai, T., Suzuki, H., Yoshida, H., MATSUSHITA, A., KAWASUMI, H., Samejima, Y., Noda, Y., Nasu, S., Tanaka, A., Morishita, N., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14251 · Cited by 21

CD8+ Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors

Takahashi, Y., Nagaya, T., Iwaya, Y., Okamura, T., Hirayama, A., Iwaya, M., Uehara, T., & Umemura, T. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07598-2 · Cited by 21

Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy

Bar-Hai, N., Ben‐Betzalel, G., Stoff, R., Grynberg, S., Schachter, J., Shapira‐Frommer, R., & Asher, N. (2023) · Cancers · doi:10.3390/cancers15113041 · Cited by 20

Association of Immune-Related Adverse Events and the Efficacy of Anti–PD-(L)1 Monotherapy in Non–Small Cell Lung Cancer: Adjusting for Immortal-Time Bias

Yu, Y., Chen, N., Yu, S., Shen, W., Zhai, W., Li, H., & Fan, Y. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1118 · Cited by 21

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Remón, J., Reguart, N., Auclin, É., & Besse, B. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.031 · Cited by 21

Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities

Garrett, N. F. M. D. S., da Costa, A. C. C., Damiani, G. B., & Vasques, C. I. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102983 · Cited by 22

Clinical burden of immune checkpoint inhibitor-induced pneumonitis

Sakamoto, K., Fukihara, J., Morise, M., & Hashimoto, N. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.05.008 · Cited by 21

Do Immune-Related Adverse Events Correlate with Response to Immune Checkpoint Inhibitors?

Saleh, K., Khalifé-Saleh, N., & Kourié, H. R. (2019) · Immunotherapy · doi:10.2217/imt-2018-0201 · Cited by 21

Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence

Eshaq, A. M., Flanagan, T. W., Abbad, A. A. B., Makarem, Z. A. A., Bokir, M. S., Alasheq, A. K., Asheikh, S. A. A., Almashhor, A. M., Binyamani, F., Al-Amoudi, W. A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010088 · Cited by 23

Elucidation of the Application of Blood Test Biomarkers to Predict Immune-Related Adverse Events in Atezolizumab-Treated NSCLC Patients Using Machine Learning Methods

Zhou, J., Wong, A. H., Wang, H., Tan, F., Chen, X., Jin, S., He, S., Shen, G., Wang, Y., Frey, B., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.862752 · Cited by 21

Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients

Iwahori, K., Uenami, T., Yano, Y., Ueda, T., Tone, M., Naito, Y., Suga, Y., Fukushima, K., Shiroyama, T., Miyake, K., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-22356-0 · Cited by 20

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer

Jiang, C. Y., Zhao, L., Green, M. D., Ravishankar, S., Towlerton, A. M. H., Scott, A. J., Raghavan, M., Cusick, M. F., Warren, E. H., & Ramnath, N. (2024) · Scientific Reports · doi:10.1038/s41598-023-48546-y · Cited by 20

Case report: reinitiating pembrolizumab treatment after small bowel perforation

Beck, T. N., Kudinov, A. E., Dulaimi, E., & Boumber, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5577-5 · Cited by 20

Correlation of Immune-Related Adverse Events and Effects of Pembrolizumab Monotherapy in Patients with Non-Small Cell Lung Cancer

Noguchi, S., Suminaga, K., Kaki, T., Kawachi, H., Fukao, A., Terashita, S., Horikawa, S., Ikeue, T., & Sugita, T. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s254146 · Cited by 20

Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma

Kobayashi, K., Iikura, Y., Hiraide, M., Yokokawa, T., Aoyama, T., Shikibu, S., Hashimoto, K., Suzuki, K., Sato, H., Sugiyama, E., et al. (2020) · In Vivo · doi:10.21873/invivo.12083 · Cited by 20

Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors

Ma, K., Jin, Q., Wang, M., Li, X., & Zhang, Y. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1617702 · Cited by 20

Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage

Conde‐Estévez, D., Monge‐Escartín, I., Ríos-Hoyo, A., Monzonís, X., Echeverría-Esnal, D., Moliner, L., Durán, X., Taus, Á., & Arriola, E. (2020) · Journal of Chemotherapy · doi:10.1080/1120009x.2020.1849488 · Cited by 19

Comparison of pembrolizumab with conventional chemotherapy after first‐line platinum‐based chemotherapy for advanced urothelial carcinoma in real‐world practice: A multicenter retrospective study

Narita, T., Hatakeyama, S., Numakura, K., Kobayashi, M., Muto, Y., Saito, M., Narita, S., Tanaka, T. D., Noro, D., Tokui, N., et al. (2021) · International Journal of Urology · doi:10.1111/iju.14601 · Cited by 19

Association of immune‐related pneumonitis with clinical benefit of anti‐programmed cell death‐1 monotherapy in advanced non‐small cell lung cancer

Ono, K., Ono, H., Toi, Y., Sugisaka, J., Aso, M., Saito, R., Kawana, S., Aiba, T., Odaka, T., Matsuda, S., et al. (2021) · Cancer Medicine · doi:10.1002/cam4.4045 · Cited by 19

Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

Yamamoto, T., Ito, T., Hase, T., Ishigami, M., Mizuno, K., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Shibata, H., et al. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1994586 · Cited by 19

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer

Takahara, Y., Tanaka, T., Ishige, Y., Shionoya, I., Yamamura, K., Sakuma, T., Nishiki, K., Nakase, K., Nojiri, M., Kato, R., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14309 · Cited by 18

White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer

Sibille, A., Henket, M. A., Corhay, J. L., Alfieri, R., Louis, R. E., & Duysinx, B. (2021) · Lung · doi:10.1007/s00408-021-00474-2 · Cited by 19

Unpleasant symptoms of immunotherapy for people with lung cancer: A mixed-method study

Zhang, J., Wang, S., Zhou, Z., Cheng, L., Yu, H., Zeng, C., Xia, X., Qiao, G., & Shi, Q. (2022) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2022.104430 · Cited by 19

Association between Early Immune-Related Adverse Events and Survival in Patients Treated with PD-1/PD-L1 Inhibitors

Zhang, Y.-C., Zhu, T.-C., Nie, R., Lu, L., Xiang, Z., Xie, D., Luo, R., & Cai, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030736 · Cited by 18

Prognostic relevance of immune-related adverse events in lung cancer patients undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Huang, Y., Ma, W., Wu, D., Lyu, M., Zheng, Q., Wang, T., Zhou, J., & Liu, C. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-299 · Cited by 18

Cascade of immunologic adverse events related to pembrolizumab treatment

Dhenin, A., Samartzi, V., Lejeune, S., & Seront, E. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-229149 · Cited by 18

Endocrine Adverse Events of Nivolumab in Non-Small Cell Lung Cancer Patients—Literature Review

Dudzińska, M., Szczyrek, M., Wojas‐Krawczyk, K., Świrska, J., Chmielewska, I., & Zwolak, A. (2020) · Cancers · doi:10.3390/cancers12082314 · Cited by 19

The association between immune-related adverse events and the prognosis of solid cancer patients treated with immunotherapy: a systematic review and meta-analysis

Xu, H., Xu, X., Ge, W., Lei, J.-J., & Cao, D. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920980546 · Cited by 17

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy

Chye, A., Allen, I., Barnet, M. B., & Burnett, D. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.894015 · Cited by 17

Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab

Economopoulou, P., Kotsantis, I., Papaxoinis, G., Gavrielatou, N., Anastasiou, Μ., Pantazopoulos, A., Kavourakis, G., Gkolfinopoulos, S., Panayiotides, I. G., Delides, A., et al. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.105013 · Cited by 17

Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients

Liu, X., Hao, N., Yang, S., Li, J., & Wang, L. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1145143 · Cited by 17

Liver dysfunction is associated with poor prognosis in patients after immune checkpoint inhibitor therapy

Yokohama, K., Asai, A., Matsui, M., Okamoto, N., Yasuoka, H., Nishikawa, T., Ohama, H., Tsuchimoto, Y., Inoue, Y. H., Fukunishi, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71561-2 · Cited by 16

Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review

Kanabar, S. S., Tiwari, A., Soran, V., Balendran, P., Price, M. J., & Turner, A. M. (2022) · Thorax · doi:10.1136/thoraxjnl-2020-215614 · Cited by 16

Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors

Chen, J., Wen, Y., Chu, X., Liu, Y., & Su, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.944342 · Cited by 16

Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Zhou, Y. L., Chen, H., Tang, L. M., Feng, Y., Tao, Y., Huang, L., Lou, N., & Shi, Y. (2023) · Immunotherapy · doi:10.2217/imt-2022-0028 · Cited by 18

Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors

Serino, M., Freitas, C., Martins, M., Ferreira, P. M., Cardoso, C. G., Veiga, F., Santos, V., Araújo, D., Bastos, H. N., Magalhães, A., et al. (2022) · Pulmonology · doi:10.1016/j.pulmoe.2022.03.003 · Cited by 15

Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature

Kyriazoglou, A. I., Liontos, M., Papadopoulos, C., Bilali, A., Kostouros, E., Pagoni, S., Doumas, K., Dimopoulos, M. A., & Bamias, A. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.11.022 · Cited by 15

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

Horinouchi, H., Nishio, M., Hida, T., Nakagawa, K., Sakai, H., Nogami, N., Atagi, S., Takahashi, T., Saka, H., Takenoyama, M., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2411 · Cited by 15

Real World Experience of Nivolumab in Non-Small Cell Lung Cancer in Korea

Lim, S. M., Kim, S.-W., Cho, B. C., Kang, J., Ahn, M., Kim, D., Kim, Y., Lee, J. S., Lee, J.-S., Lee, S. Y., et al. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.245 · Cited by 15

Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab

Okamoto, I., Sato, H., & Tsukahara, K. (2020) · Auris Nasus Larynx · doi:10.1016/j.anl.2020.04.001 · Cited by 15

Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma

Zhao, J., Wen, X., Ding, Y., Li, D., Zhu, B., Li, J., Weng, D., Zhang, X., & Zhang, X. (2020) · Aging · doi:10.18632/aging.103285 · Cited by 15

Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?

Chmielewska, I., Dudzińska, M., Szczyrek, M., Świrska, J., Wojas‐Krawczyk, K., & Zwolak, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257484 · Cited by 16

A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer

Hamada, K., Yoshimura, K., Oshinomi, K., Hirasawa, Y., Ariizumi, H., Ohkuma, R., Shida, M., Kubota, Y., Matsui, H., Ishiguro, T., et al. (2022) · Medicine · doi:10.1097/md.0000000000028339 · Cited by 15

Single pembrolizumab treatment causing profound durable response in a patient with pulmonary pleomorphic carcinoma

Tokuyasu, H., Ishikawa, S., Sakai, H., Ikeuchi, T., & Miura, H. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.100879 · Cited by 15

Management of metabolic adverse events of targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper

Silvestris, N., Argentiero, A., Beretta, G. D., Bartolo, P. D., Montagnani, M., Danesi, R., Ferrari, P., D’Oronzo, S., Gori, S., Russo, A. D., et al. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103066 · Cited by 16

Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Hosoya, K., Fujimoto, D., Morimoto, T., Kumagai, T., Tamiya, A., Taniguchi, Y., Yokoyama, T., Ishida, T., Hirano, K., Matsumoto, H., et al. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.003 · Cited by 43

Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab

Toi, Y., Sugawara, S., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Tsurumi, K., Suzuki, K., Shimizu, H., Sugisaka, J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0384 · Cited by 294

Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program

Baldini, E., Lunghi, A., Cortesi, E., Turci, D., Signorelli, D., Stati, V., Melotti, B., Ricciuti, B., Frassoldati, A., Romano, G., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.014 · Cited by 43

Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab

Bouhlel, L., Doyen, J., Chamorey, E., Poudenx, M., Ilié, M., Gal, J., Guigay, J., Benzaquen, J., Marquette, C., Berthet, J., et al. (2020) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.04.019 · Cited by 26

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab

Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.019 · Cited by 377